BioMedNewsBreaks

FridayOct 15, 2021 11:07 am

BioMedNewsBreaks – Why Nemaura Medical Inc. (NASDAQ: NMRD) Is ‘One to Watch’

Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing affordable diagnostic and digital tools for chronic disease management. Founded in 2011, the company set out to create a single platform technology to measure blood markers at the surface of the skin. Since then, it has evolved with the creation of wearable technologies and digital health care solutions that encourage and empower people to take charge of their own health and wellbeing. “Its flagship product, sugarBEAT(R), is a wearable, non-invasive, and flexible continuous glucose monitor (‘CGM’) designed to help people with diabetes and pre-diabetes manage their glucose levels. Insulin users…

Continue Reading

WednesdayOct 13, 2021 10:37 am

BioMedNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) Guides Demonstrate Significant Reduction of Pediatric Tooth Decay in Peer-Reviewed Study

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced results from a peer-reviewed, published study by an independent dentist. The findings demonstrate a significant reduction of tooth decay in pediatric patients after undergoing treatment using the company’s FDA Class 1 registered Vivos Guide, a flexible, BPA-free base polymer intraoral device. A preformed positioner intended to prevent a child’s teeth from shifting and may seal the lips to convert mouth breathing to nose breathing, the Vivos Guide is worn…

Continue Reading

TuesdayOct 12, 2021 11:29 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at KSCA Psychedelics Virtual Investor Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the KCSA Psychedelics Virtual Investor Conference at 3:00 p.m. ET on Oct. 14, 2021. The event is slated to take place virtually on Oct. 13-14, 2021. Tryp’s Chief Financial Officer Luke Hayes will provide a live overview of the company's activities and elaborate on how Tryp is leading the next wave of psychedelic drug development beyond mental health with its focus on chronic pain and other indications. Interested parties should visit https://ibn.fm/1Y2RX to…

Continue Reading

MondayOct 11, 2021 2:22 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Providing Reliable, Consistent Dose Administration and Monitoring Devices

RYAH Group (CSE: RYAH), a connected device and big data and technology company, offers a suite of precision intake control and management devices that provide a practical way to execute volume control guidelines safely. In a company blog post, discussed in a recent article, RYAH noted that a global task force had created three separate dosing protocols: routine administration, conservative administration and rapid administration, with each designed to ease a patient treating chronic pain into medical cannabis and treatment with THC if needed. Such dosing guidelines are just half of the equation. The other half is the delivery mechanism, as…

Continue Reading

MondayOct 11, 2021 1:42 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Stands Distinct in World of Cancer Prevention, Treatment

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a proven early thought leader and developer of multi-cancer (also called pan-cancer) ideas and technology. “AnPac Bio is one of the first companies in the world to produce major theories and methods of multi-level, multi-parameter and multi-cancer screening. The innovative technology has opened up a new field in early cancer screening that is based on a biophysical property and has achieved significant results,” reads a recent article. AnPac Bio has one of the largest sample libraries in the world, with more than 220,000 samples…

Continue Reading

MondayOct 11, 2021 1:27 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Preparing for Clinical Trials Amid Growing Push for New Federally Approved Therapeutic

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) expects to soon launch a phase 2a clinical trial to determine the efficacy of its psychedelic drug candidate TRP-8802 in treating Prader-Willi Syndrome, hypothalamic obesity eating disorder resulting from removal of a brain tumor, and binge eating disorder. According to a recent article, TRP-8802 will be used in combination with psychotherapy under professional care to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect. Tryp then plans to proceed into phase 2b clinical trials with drug candidate TRP-8803 to test the trademarked product’s ability to penetrate the natural blood-brain…

Continue Reading

MondayOct 11, 2021 9:54 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Berubicin’s Impressive Potential in Syndicated Broadcast

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. According to the update, the audio press release covers CNS Pharmaceuticals’ recent announcement of dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types…

Continue Reading

FridayOct 08, 2021 11:36 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Poised to Become Global Leader in Manufacture of Rare Cannabinoids

InMed Pharmaceuticals (NASDAQ: INM) recently announced it had signed a definitive agreement to acquire 100% of BayMedica Inc., a U.S.-based private company specializing in the manufacture and commercialization of rare cannabinoids. InMed CEO Eric A. Adams described the acquisition as a transformative transaction for the company as it would give InMed a breadth of synthetic cannabinoid manufacturing capabilities. “BayMedica brings unparalleled cannabinoid manufacturing expertise in both chemical synthesis and biosynthesis together with industry veterans who have been pioneers in this space,” a recent article quotes Adams as saying. The article further notes that, once closed, the transaction will create a…

Continue Reading

TuesdayOct 05, 2021 1:04 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Participate at Upcoming LD Micro Main Event

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, has announced that it will be featured at the 14th annual LD Micro Main Event conference; the conference will be a virtual event. As part of the company’s presence at the conference, NMRD CEO Faz Chowdhury, PhD, will present an overview of the company. That presentation is scheduled for Oct. 13, 2021, at 10 a.m. ET. To view the full presentation, visit https://ibn.fm/QtCSC To view the full press release, visit https://ibn.fm/KjeJg About Nemaura Medical Inc. Nemaura Medical…

Continue Reading

TuesdayOct 05, 2021 11:55 am

BioMedNewsBreaks – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Featured in Latest Episode of ‘Bell2Bell’ Podcast

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) was featured in the “Bell2Bell Podcast,” a part of IBN’s (“InvestorBrandNetwork”) sustained effort to provide specialized content distribution via widespread syndication channels. Avricore Health’s CEO Hector Bremner joined the latest episode to discuss the company’s business model and its continuing efforts to lead the charge and improve early detection and screening practices throughout the health care industry. “We’re a company focused on diagnostics. We place a system within the pharmacy where a blood test or a molecular test can be done. A simple sample is collected, and the whole test takes about 15 minutes,”…

Continue Reading